The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) held today approved a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 in the previous year. The in-person meeting took place near the company's headquarters in Berlin, with 55.37% of the share capital represented. Shareholders endorsed the actions of the Executive Board and Supervisory Board for the fiscal year 2025 and approved all agenda items by a large majority.
The increased dividend underscores Eckert & Ziegler's financial health and its ability to generate value for shareholders. As a leading specialist in isotope-related components for nuclear medicine and radiation therapy, the company has demonstrated consistent growth. The detailed voting results and the CEO's presentation are available on the Eckert & Ziegler website.
Eckert & Ziegler SE employs over 1,000 people and offers a broad range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. The company's shares are listed in the TecDAX index of Deutsche Börse. This dividend increase signals confidence in the company's future prospects and its ongoing commitment to rewarding shareholders.
For more information about the company and its services, visit the official website at www.ezag.com.
